02 June 2020 | Views
Dilip Shanghvi, Managing Director, Sun Pharma, Mumbai talks about the company's latest contribution to the COVID-19 fight
"Sun Pharma is constantly evaluating potential targets that can be explored for treating Covid-19 patients. Nafamostat has shown promising data against SARS-CoV-2 virus in in vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea. We believe it holds promise in the treatment of COVID-19 patients."
- Dilip Shanghvi, Managing Director, Sun Pharma, Mumbai